SEATTLE — Researchers who have established the level of bone mineral density (BMD) change that can serve as a surrogate endpoint in anti-osteoporosis drug clinical trials have now also determined the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback